

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Attorney Docket Number	015270-008930US
------------------------	-----------------

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AD	WO	99/60024	A1	11-25-1999			<input type="checkbox"/>
	AE	WO	99/06545	A2	02-11-1999			<input type="checkbox"/>
	AF	WO	91/16819	A1	11-14-1991			<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Date Considered

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MH	AG	CHAPMAN, P.F., "Model behaviour," <i>Nature</i> , 408:915-916 (2000).	
	AH	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000).	
	AI	DEMATTOIS et al., "Peripheral anti A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , 10:1-6 (2001).	
	AJ	ELAN, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1782," Press Release of 1/28/02.	
	AK	ELAN, "Elan and Wyeth provide update on status of Alzheimer's collaboration," Press Release of 3/1/02.	
	AL	ESIRI, M.M., "Is an effective immune intervention for Alzheimer's disease in prospect?," <i>Trends in Pharmacological Sciences</i> , 22(1):2-3	
	AM	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>Journal of Neuroimmunology</i> , 88:85-90 (1998).	
	AN	FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <i>PNAS</i> , 97(21):11455-11459 (2000).	
	AO	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <i>Journal of Neuroimmunology</i> , 95:136-142 (1999).	
	AP	FRIEDLAND et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease a,b," from <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Science, NY, NY, pages 242-247 (1997).	
	AQ	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> , 373(6514):523-527 (1995).	
	AR	GRUBECK-LOEBENSTEIN et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?," <i>TINS</i> , 23(3):114 (2000).	
	AS	JEN et al., "Preparation and purification of antisera against different regions or isoforms of β -amyloid precursor protein," <i>Brain Research Protocols</i> , 2:23-30 (1997).	
	AT	JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
	AU	LEMERE et al., "Nasal A β Treatment Induces Anti-A β Antibody Production and Decreases Cerebral Amyloid Burden in PD-APP Mice," <i>Annals of NY Acad. Sci.</i> , 920:328-331 (2000).	
✓	AV	MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MH	AW	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	
	AX	RASO, V., "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , abstract, (1999).	
	AY	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	
	AZ	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotechnology</u> , 18(1):34-39 (2000).	
	BA	SMALL et al., "Alzheimer's disease and A β toxicity: from top to bottom," <u>Nat. Rev. Neurosci.</u> , 2(8):595-598 (2001).	
	BB	ST GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 400:116-117 (1999).	
✓	BC	YOUNKIN, S.G., "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7(1):18-19 (2001).	

Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	Unassigned		
		Filing Date	October 31, 2003		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	015270-008930US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
MH	AA	2002/0197258 A1	12-26-2002	Ghanbari et al.	

Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number				10/698,099	
Filing Date				October 31, 2004	
First Named Inventor				Schenk, Dale B.	
Art Unit				1614	
Examiner Name				Unassigned	
Attorney Docket Number				015270-008930US	

[illegible][illegible]

Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1614
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
MH	AD	BODLES et al., "Toxicity of non-A β component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β -sheet structure and fibrils," <u>Eur J. Biochem.</u> , 267:2186-2194 (2000).		
	AE	CAO et al., "Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease," Program No. 594.13, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience, 2002.		
	AF	CULVENOR et al., "Non-A β Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and α -Synuclein Are Not Associated with A β Amyloid," <u>Am. J. Pathology</u> , 155(4):1173-1181 (1999).		
	AG	HASHIMOTO et al., "Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease," <u>Brain Pathology</u> , 9:707-720 (1999).		
	AH	HSU et al., " α -Synuclein Promotes Mitochondrial Deficit and Oxidative Stress," <u>Am. J. Pathology</u> , 157(2):401-410 (2000).		
	AI	JENSEN et al., "Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide," <u>Biochem. J.</u> , 310(Pt 1):91-94 (1995).		
	AJ	MASLIAH et al., "Dopaminergic Loss and Inclusion Body Formation in α -Synuclein Mice: Implications for Neurodegenerative Disorders," <u>Science</u> , 287:1265-1268 (2000).		
	AK	NCBI database search result for P37840 Alpha-synuclein conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&DB=protein&list_uids=58		
	AL	NCBI database search result for NP_009292 synuclein, alpha conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list_uids=68		
V	AM	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," <u>PNAS</u> , 90:11282-11286 (1993).		

Examiner Signature	/Michelle Horning/	Date Considered	11/07/2006
-----------------------	--------------------	--------------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.